Clinical trials are research studies to collect data, measure outcomes and assess the safety and effectiveness of a new drug or combination of drugs.
Deciphera has completed a clinical Phase 1 trial on rebastinib (DCC-2036), and has established its safety and tolerability. A recommended phase 2 dose of 150 mg twice daily has been determined. Rebastinib potently inhibits TIE-2 kinase, and will be evaluated in a Phase 1B trial as an anti-angiogenic beginning Q3 2013. As a potent inhibitor of the angiopoietin tumor vascularization pathway, Rebastinib will be evaluated as a single agent and in combination with anti-VEGF and chemotherapeutic agents.
Deciphera is targeting clinical development of DCC-2701 in 2013, with an IND submission in Q3 to enable Phase 1 evaluation in glioma patients.
Additional information about clinical trials is available at www.clinicaltrials.gov.